Pascal Touchon

Pascal serves as Global Strategy Advisor to RoslinCT and board director, bringing over four decades of international experience in the biopharmaceutical industry, combining operational leadership with strategic vision to accelerate the development of transformative therapies for patients worldwide. He has held senior roles across large pharmaceutical companies and biotech innovators, with a consistent focus on harnessing cutting-edge science to deliver meaningful clinical impact.

Formerly Global Head of Strategy and Business Development, as well as Global Head of the Cell & Gene unit at Novartis Oncology, Pascal played a pivotal role in the development and global launch of Kymriah (R) the first approved cell and gene therapy in the U.S. He later served as CEO of Atara Biotherapeutics, where he led the company through the first ever approval of an allogeneic T Cell therapy, Ebvallo (R). He currently serves as Chairman of the Board at Atara, sits on the boards of Ipsen (IPN) Medincell (MEDCL), Catalym and CDR-Life , and is an Operating Partner at Jeito Capital, bringing strategic insight and operational expertise to support sustainable value creation.

Pascal holds a Doctorate in Veterinary Medicine from Paul Sabatier University and an MBA from INSEAD. He has lived and worked extensively across Asia, Europe and the United States, bringing a truly global perspective to his board and advisory roles.